Jay S Stout insider trades: Immunovant (IMVT) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jay reports to the SEC
Open-market buys and sales
19 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 21, 2026 | IMVT | ↓ Sell | 2,595 | $28.94 | $75K | Direct | Oct 23, 2026 (2d) |
| Oct 7, 2026 | IMVT | ↓ Sell | 3,809 | $32.06 | $122K | Direct | Oct 9, 2026 (2d) |
| Jul 23, 2026 | IMVT | ↓ Sell | 2,857 | $38.69 | $111K | Direct | Jul 24, 2026 (1d) |
| Jul 8, 2026 | IMVT | ↓ Sell | 3,487 | $39.55 | $138K | Direct | Jul 10, 2026 (2d) |
| Jun 26, 2026 | IMVT | ↓ Sell | 40,000 | $38.31 | $1.5M | Direct | Jun 26, 2026 (0d) |
| Apr 8, 2026 | IMVT | ↓ Sell | 10,132 | $24.83 | $252K | Direct | Apr 10, 2026 (2d) |
| Jan 21, 2026 | IMVT | ↓ Sell | 1,977 | $26.03 | $51K | Direct | Jan 23, 2026 (2d) |
| Jan 7, 2026 | IMVT | ↓ Sell | 1,203 | $26.53 | $32K | Direct | Jan 9, 2026 (2d) |
| Oct 22, 2025 | IMVT | ↓ Sell | 2,520 | $19.03 | $48K | Direct | Oct 24, 2025 (2d) |
| Oct 8, 2025 | IMVT | ↓ Sell | 1,585 | $16.30 | $26K | Direct | Oct 10, 2025 (2d) |
| Jul 23, 2025 | IMVT | ↓ Sell | 2,805 | $18.15 | $51K | Direct | Jul 25, 2025 (2d) |
| Jul 9, 2025 | IMVT | ↓ Sell | 1,519 | $17.24 | $26K | Direct | Jul 11, 2025 (2d) |
| Apr 23, 2025 | IMVT | ↓ Sell | 1,925 | $14.79 | $28K | Direct | Apr 25, 2025 (2d) |
| Apr 9, 2025 | IMVT | ↓ Sell | 5,004 | $12.99 | $65K | Direct | Apr 11, 2025 (2d) |
| Jan 22, 2025 | IMVT | ↓ Sell | 2,195 | $23.59 | $52K | Direct | Jan 24, 2025 (2d) |
| Oct 23, 2024 | IMVT | ↓ Sell | 2,740 | $29.53 | $81K | Direct | Oct 25, 2024 (2d) |
| Jul 24, 2024 | IMVT | ↓ Sell | 2,813 | $27.76 | $78K | Direct | Jul 26, 2024 (2d) |
| Apr 24, 2024 | IMVT | ↓ Sell | 7,239 | $28.90 | $209K | Direct | Apr 26, 2024 (2d) |
| Apr 24, 2018 | VSAR | ↓ Sell | 4,854 | $1.55 | $8K | Direct | Apr 25, 2018 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other IMVT insiders
Open-market trades in the last 12 months
About Jay S Stout's insider trades
Jay S Stout is Chief Technology Officer at Immunovant (IMVT). Since Apr 24, 2018, Jay has reported no open-market purchases and 19 sales worth $3.0M on SEC Form 4. In the last 12 months: 8 sales ($2.3M).
Their filings also include grants and awards (7 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IMVT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.